A perfect balance of optical imaging technologies and screening expertise is offered through the partnership between Carl Zeiss and Cellomics, MLSCN research objectives including automation for target-based and cell-based phenotypic assay implementation, software for managing molecular library screening operations, and informatics tools for screening data management comprise the suite of tools that will speed the discovery of molecular research in the public sector.
 High content screening has accelerated drug and research tool development in the pharmaceutical industry.  Automated fluorescence imaging and image analysis, data mining, compound management, screen quality control, and auditable screen development are among the suite of tools available to MLI investigators.  Cellomics® High Content Informatics (HCi™) software platform is an integral part of this suite for compound screening
and Structure Activity Relationship (SAR) analyses. “At the core of HCi is the Cellomics Store database, a highly scalable warehouse for assay protocols, images, and data that will enable screening center inter-operability” states Dr. Mark Collins, Sr. Product Manager for Informatics at Cellomics.
 “Carl Zeiss is pleased to be a partner with Cellomics.  Between our two companies, we have a continuum of research tools for MLI investigators ranging from high resolution imaging to ultra-high throughput” commented James Sharp, President of Carl Zeiss MicroImaging and Chairman of the Board for Cellomics.  “Carl Zeiss, in partnership with Cellomics will bring many years of experience in screening within the Drug Discovery field to screening centers of the MLSCN,” added Daniel J. Calvo, President and CEO of Cellomics.

About Carl Zeiss

Carl Zeiss is a leading international group of companies operating worldwide in the optical and opto-electronic industry. The company is headquartered in Oberkochen, Germany. The Carl Zeiss Group is structured as six business groups that operate with sole responsibility. They are generally ranked first or second in their three strategic markets of biosciences and medical technology, system solutions for industry and optical consumer goods. They offer products and services for biomedical research and medical technology, system solutions for the semiconductor, automotive and mechanical engineering industries, as well as high quality consumer goods such as eyeglass lenses, camera lenses and binoculars.
The company is represented in more than 30 countries and operates production facilities in Europe, America and Asia. In fiscal year 2002/2003 the global workforce of approximately 14,000 employees generated revenue of about EUR 2 billion. For more information about Carl Zeiss, visit our website at www.zeiss.com.

About Cellomics

Cellomics, Inc. is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology groups by offering complete systems for High Content Screening (HCS).  The platform includes HCS instrumentation (both fixed end-point and kinetic systems), informatics, cellular image analysis software (BioApplications), fluorescent reagents, kits, cell lines, and multiparametric assays.  When applied to early drug discovery, this platform is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as enhancing throughput in systems biology and basic research. Cellomics’ proprietary platforms, including the ArrayScan® and KineticScan® HCS Readers, along with BioApplications software and High Content Informatics (HCi™) suite, are in use at multiple sites within all of the top fifteen pharmaceutical companies, as well as leading pharmaceutical and biotechnology companies and academic centers globally. For more information about Cellomics, visit our website at www.cellomics.com.

For further information please contact:

Carl Zeiss MicroImaging
Marina Yurovitsky
Marketing Comm. Manager
One Zeiss Drive
Thornwood, NY  10594
914-681-7645
914-681-7445 (fax)

www.zeiss.com/micro

Cellomics, Inc.
Judy P. Masucci, Ph.D.
Director of Marketing
100 Technology Drive
Pittsburgh, PA 15219
412-770-2200 x 2353
412-770-2450 (fax)

www.cellomics.com